Literature DB >> 22773277

Relative survival of patients with supratentorial low-grade gliomas.

Nicolas R Smoll1, Oliver P Gautschi, Bawarjan Schatlo, Karl Schaller, Damien C Weber.   

Abstract

We sought to assess the population-based estimates of age-standardized survival among patients with low-grade gliomas (LGG) and to determine the impact of age and time on relative survival (RS). Data from the Surveillance, Epidemiology, and End Results (SEER) program of NCI from 1973 through 2006 were analyzed to assess survival among 5037 patients. Relationships were modeled using Dickman's piecewise constant hazards RS model. The 3- and 10-year age-standardized RS were 67% and 37%, respectively. When analyzed by age group, the 10-year overall survival (OS) and RS for children (age, <16 years), young adults (age, 16-39 years), adults (age, 40-64 years), and older patients (age, ≥65 years) were 86% and 86%, 61% and 62%, 40% and 43%, and 10% and 14%, respectively. The observed difference between OS and RS was larger among older patients (4%) and smallest among children (<1%). Older patients were 30.5 times (excess hazard ratio [eHR]; 95% confidence interval [CI], 20.3-50.0) as likely as young adults to die during the first year and 18.2 times as likely to die during the second year. Adults were 5.3 (eHR; 95% CI, 3.5-8.1) times as likely to die during their first year as young adults. In the remaining years, the observed survival differences were substantially decreased, and the presence of an age-by-follow-up interaction was observed. Survival among older patients with LGG was substantially different from the one computed for young adults and children. Despite the hazards across age groups not being proportional, RS does not provide additional information, compared with OS, in patients with LGG.

Entities:  

Mesh:

Year:  2012        PMID: 22773277      PMCID: PMC3408266          DOI: 10.1093/neuonc/nos144

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  26 in total

1.  Regression models for relative survival.

Authors:  Paul W Dickman; Andy Sloggett; Michael Hills; Timo Hakulinen
Journal:  Stat Med       Date:  2004-01-15       Impact factor: 2.373

2.  Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.

Authors:  M P W A Houben; K K H Aben; J L J M Teepen; A Y N Schouten-Van Meeteren; C C Tijssen; C M Van Duijn; J W W Coebergh
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

3.  Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy.

Authors:  Luigi Mariani; Gianluca Deiana; Erik Vassella; Ali-Reza Fathi; Christine Murtin; Marlène Arnold; Istvan Vajtai; Joachim Weis; Peter Siegenthaler; Martina Schobesberger; Michael M Reinert
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

Review 4.  Epidemiology and etiology of gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2005-02-01       Impact factor: 17.088

5.  Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.

Authors:  C Walker; B Haylock; D Husband; K A Joyce; D Fildes; M D Jenkinson; T Smith; J Broome; D G du Plessis; P C Warnke
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

6.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.

Authors:  M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

7.  Prognostic factors for survival in adult patients with cerebral low-grade glioma.

Authors:  Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

8.  Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.

Authors:  Abul B M F Karim; Denes Afra; Philippe Cornu; Norman Bleehan; Simon Schraub; Olivier De Witte; François Darcel; Sally Stenning; Marianne Pierart; Martine Van Glabbeke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

9.  Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001.

Authors:  Elizabeth B Claus; Peter M Black
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

10.  EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas.

Authors:  Mirta Varela; Stella Maris Ranuncolo; Ana Morand; José Lastiri; Elisa Bal De Kier Joffé; Lydia Inés Puricelli; María Guadalupe Pallotta
Journal:  J Surg Oncol       Date:  2004-04-01       Impact factor: 3.454

View more
  20 in total

1.  Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy.

Authors:  Ze-Shun Zhang; Jing Wang; You-Bi Shen; Cheng-Cheng Guo; K E Sai; Fu-Rong Chen; Xin Mei; F U Han; Zhong-Ping Chen
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

2.  Arterial spin labeling MR imaging for differentiation between high- and low-grade glioma-a meta-analysis.

Authors:  Alberto Falk Delgado; Francesca De Luca; Danielle van Westen; Anna Falk Delgado
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

3.  High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas.

Authors:  Lei Wang; Luyao Zhang; Weigao Shen; Yanbo Liu; Yinan Luo
Journal:  Exp Ther Med       Date:  2015-12-02       Impact factor: 2.447

4.  Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma.

Authors:  Shervin Tabrizi; Beow Y Yeap; Janet C Sherman; Lisa B Nachtigall; Mary K Colvin; Michael Dworkin; Barbara C Fullerton; Juliane Daartz; Trevor J Royce; Kevin S Oh; Tracy T Batchelor; William T Curry; Jay S Loeffler; Helen A Shih
Journal:  Radiother Oncol       Date:  2019-05-10       Impact factor: 6.280

5.  Diagnostic challenges, management and outcomes of midline low-grade gliomas.

Authors:  Mueez Waqar; Shahid Hanif; Nitika Rathi; Kumar Das; Rasheed Zakaria; Andrew R Brodbelt; Carol Walker; Michael D Jenkinson
Journal:  J Neurooncol       Date:  2014-08-06       Impact factor: 4.130

6.  Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.

Authors:  Pei Yang; Yongzhi Wang; Xiaoxia Peng; Gan You; Wei Zhang; Wei Yan; Zhaoshi Bao; Yinyan Wang; Xiaoguang Qiu; Tao Jiang
Journal:  J Neurooncol       Date:  2013-03-13       Impact factor: 4.130

Review 7.  Molecular and genetic pathways in gliomas: the future of personalized therapeutics.

Authors:  Ryan Grant; Luis Kolb; Jennifer Moliterno
Journal:  CNS Oncol       Date:  2014-03

8.  Incidence and relative survival of anaplastic astrocytomas.

Authors:  Nicolas R Smoll; Brett Hamilton
Journal:  Neuro Oncol       Date:  2014-04-09       Impact factor: 12.300

9.  Neurocognitive effects of proton radiation therapy in adults with low-grade glioma.

Authors:  Janet Cohen Sherman; Mary K Colvin; Sarah M Mancuso; Tracy T Batchelor; Kevin S Oh; Jay S Loeffler; Beow Y Yeap; Helen A Shih
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

10.  GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.

Authors:  Xiang Zhou; Fazheng Shen; Pengju Ma; Hongyan Hui; Sujuan Pei; Ming Chen; Zhongwei Wang; Wenke Zhou; Baozhe Jin
Journal:  Mol Med Rep       Date:  2015-07-28       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.